Sex differences in the safety of S‐1 plus oxaliplatin and S‐1 plus cisplatin for patients with metastatic gastric cancer

Previous studies have shown sex‐related differences in the incidence of adverse events following treatment with fluoropyrimidines, however the mechanism of this difference is unknown. We examined sex‐related differences in the safety of S‐1 plus oxaliplatin (SOX) and S‐1 plus cisplatin (CS) in 663 m...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Cancer Sci
Autori principali: Yamada, Yasuhide, Koizumi, Wasaburo, Nishikawa, Kazuhiro, Gotoh, Masahiro, Fuse, Nozomu, Sugimoto, Naotoshi, Nishina, Tomohiro, Amagai, Kenji, Chin, Keisho, Niwa, Yasumasa, Tsuji, Akihito, Imamura, Hiroshi, Tsuda, Masahiro, Yasui, Hirofumi, Fujii, Hirofumi, Yamaguchi, Kensei, Yasui, Hisateru, Hironaka, Shuichi, Shimada, Ken, Hyodo, Ichinosuke
Natura: Artigo
Lingua:Inglês
Pubblicazione: John Wiley and Sons Inc. 2019
Soggetti:
Original Articles
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC6726691/
https://ncbi.nlm.nih.gov/pubmed/31254422
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/cas.14117
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi